TNFa and Serum Galectin-3 in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction, Insulin Resistance and Type 2 Diabetes Mellitus

Bolotskykh, Ganna; Rudyk, Iurii

doi:10.1016/j.cardfail.2014.06.071

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Galectin-3 was correlated with the VEGF-A level Diabetic cardiomyopathy Bolotskykh and Rudyk 2014 [82] Cross-sectional study 74 patients with HFpEF with and without T2D…”

Section: Galectin-in Type 1 Diabetesmentioning

confidence: 99%

“…Jelena et al enrolled 189 participants with T2D and/or arterial hypertension (HT), and found that levels of galectin-3 were higher in patients with both T2D and HT, and correlated with left ventricular (LV) mass, indicating the potential role of Galectin-3 for early detection of myocardial structural and functional alterations [81]. Bolotskykh et al found that nondiabetic patients with heart failure are accompanied by insulin resistance, and the levels of Galectin-3, TNF-α and insulin in such heart failure patients are significantly increased [82]. Myocardial inflammation and fibrosis are accompanied by changes in the Galectin-3 concentration [83].…”

Section: Diabetic Cardiomyopathymentioning

confidence: 99%

See 1 more Smart Citation

Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot

Tian

Zhang

et al. 2022

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Galectin-3 is a member of the galectin family, widely expressed in immune cells and plays a role mainly in inflammation, autoimmunity, apoptosis, and chemotaxis. We summarized the roles of Galectin-3 in diabetes and its complications, as well as the underlying mechanisms. Clinical research has determined that the circulating level of Galectin-3 is closely related to diabetes and its complications, thus it is promising to use Galectin-3 as a predictor and biomarker for those diseases. Galectin-3 also may be considered as an ideal therapeutic target, which has broad prospects in the prevention and treatment of diabetes and its complications, especially macrovascular and microvascular complications.

show abstract

“…Galectin-3 was correlated with the VEGF-A level Diabetic cardiomyopathy Bolotskykh and Rudyk 2014 [82] Cross-sectional study 74 patients with HFpEF with and without T2D…”

Section: Galectin-in Type 1 Diabetesmentioning

confidence: 99%